Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Cassava Sciences Inc (FLNA) vs Hewlett Packard Enterprise Co (HPE) Price & Performance

Cassava Sciences IncTrade
Hewlett Packard Enterprise CoTrade

Price performance (Past 24H)

Key statistics

Cassava Sciences Inc vs Hewlett Packard Enterprise Co — how do they compare? Cassava Sciences Inc trades at $0.94 (market cap $47.75M), while Hewlett Packard Enterprise Co trades at $55.95 (market cap $72.01B). The key difference: Hewlett Packard Enterprise Co is far larger — about 1508.1× Cassava Sciences Inc's market cap, and Hewlett Packard Enterprise Co pays a 1.05% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.

FLNAHPE
Market Cap
$47.75M$72.01B
Sector
HealthTechnology
52-Week High
$4.64$56.14
52-Week Low
$0.87$20.01
Enterprise Value
-$34.93M$87.96B
Dividend Yield
1.05%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Cassava Sciences Inc

FLNA trades at $0.9973, up 0.23% with a bearish technical signal despite recent earnings beats. The company shows negative profitability with ROE at -55.79% and ROA at -35.34%, though cash burn improved from -$33M to -$30M projected for 2026. Analyst consensus is strongly bullish with 8 buy ratings versus 4 hold ratings.

The outlook remains challenging due to persistent losses and negative cash flow, but analyst optimism and continued progress in TSC-related epilepsy therapies provide potential catalysts. Key risks include execution challenges in clinical development and the company's ability to secure additional funding.

Hewlett Packard Enterprise Co

HPE stock trades at $54.67, up 2.72% recently, with a bullish technical signal from moving averages but overbought RSI readings. The company has beaten earnings estimates in recent quarters, with Q2 2026 EPS expected at $0.925. Revenue grew to $34.30B in 2025, though net income fell sharply to $57M due to high investing cash outflows. Analysts maintain a consensus buy rating with a $69.81 price target, citing AI infrastructure demand.

The outlook is positive given AI-driven upgrades and institutional buying, but risks include volatile cash flows, elevated debt, and margin pressure. Investors should weigh strong analyst sentiment against execution risks in a competitive market.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Cassava Sciences Inc

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease

Read more on FLNA

About Hewlett Packard Enterprise Co

Hewlett Packard Enterprise is an information technology vendor that provides hardware and software to enterprises. Its primary product lines are compute servers, storage arrays, and networking equipment.

Read more on HPE